CHECKIT
John Wilson
CEO
We have worked with Yellowstone Advisory for a number of years and they transformed our investor relations strategy which significantly increased the interest of our business to both institutional and retail investors. We have been impressed by their understanding of the smaller companies market and their results focussed approach to IR. I would recommend their services without hesitation.
EQUINITI
Guy Wakeley
CEO
Yellowstone Advisory provided valuable input into the interim results announcement and presentation, helping to ensure the investment messaging was consistent throughout the documents. Great relationships and credibility with investors enables them to solicit useful feedback which we have used in developing our future investor messaging.
.png){kind=small}
Oxford Biodynamics Plc: FY results webinar
Wed 17 Jan
|Webinar
Jon Burrows, CEO presents the FY results which are released on 17 January and updates on current performance.
Time & Location
17 Jan 2024, 15:00 – 16:00
Webinar
About the event
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which has been launched in the US and UK in September 2023. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit, which is available for purchase by the life science research community. The Company's product portfolio is based on a…